



Male Contraceptive Initiative  
811 Ninth Street, Suite 120 #255  
Durham, NC 27705  
984.464.2951

**Title:** Male Contraceptive Initiative Fellowship Program - 2022

**Funding Announcement:** 2022-AB

**Posted Date:** February 1st, 2022

**Application Due Date:** April 15th, 2022

**Intended Start Date:** August 1st, 2022

## Section I: Funding Opportunity Description

**Purpose:** The Male Contraceptive Initiative Fellowship Program offers support for up to two years for domestic and international predoctoral and postdoctoral trainees focusing on projects related to the research and development of novel contraceptives that inhibit sperm production or impact sperm quality.

**Background:** Male Contraceptive Initiative (MCI), a US-based 501(c)3 nonprofit, is a funding agency and advocate for safe, effective, and reversible contraceptive solutions for those that produce sperm.

Worldwide, nearly half of all pregnancies are unintended. Furthermore, current contraceptive options do not adequately meet the needs of users who desire contraception. Contraceptive users who produce sperm are limited to condoms and vasectomy, which do not provide adequate diversity in characteristics to meet the needs of all users. The emphasis of this work is to provide early stage career support to researchers in fields related to the development of contraceptives for those who produce sperm, and encourage further research in the basic science underlying male fertility and infertility.

## Section II: Fellowship details

MCI Pre-doctoral Fellowships provide two years of support with a stipend of up to \$40,000 USD / year. MCI Post-doctoral Fellowships provide two years of support with a stipend of up to \$60,000 USD / year. Funds are for coverage of tuition (if required), salary, and fringe benefits such as healthcare. Other expenses including facilities & administrative costs (F&A) are not allowed.

Other benefits associated with MCI Fellowships include access to MCI resources and networks, promotional outlets such as webinars and meetings, connection to experts and key opinion leaders, and other support from MCI staff.

To adjust for differences in global living cost, stipends may be subject to country-related discounts and will be informed by standard rates for government pre- and postdoctoral fellowships in the location where the applicant will perform the work. We advise applicants from countries where maximum stipend amount is limited by policy or where legal or tax regulations are applicable to contact the appropriate MCI officer at the earliest available opportunity.

MCI Fellows will receive support for up to two years, with second year renewal contingent on submission and approval of a first year progress report as well as availability of funds. Fellowships or fellowship funds are not transferable to other persons or items.

Fellows are expected to secure any additional funding necessary in the post-project period. Multiple fellowships are expected to be awarded in relation to this announcement.

## Section III: Eligibility requirements

Applicants must be either pursuing a PhD or employed as a postdoctoral trainee with a research focus applicable to contraception.

Applicants need not be citizens or residents of the United States. Applicants must be sponsored by a principal investigator who is affiliated full-time with an accredited academic institution, has ongoing research activity involving male contraception, and agrees to supervise the applicant's training.

Institutions need not be in the United States. Eligible institutions include accredited domestic and foreign non-profit institutions, public and private universities, colleges, foundations, and hospitals.

### Fields of study

This application is open to all projects relevant to the development of male contraceptives. This includes, but is not limited to, the research and development of male contraceptives, basic science of male contraceptive targets, and tools that are broadly applicable to the development of male contraceptives.

Acceptable fields of study include, but are not limited to, molecular and cell biology, andrology, reproductive biology, pharmacology and toxicology, medicinal chemistry, structural biology, developmental biology, endocrinology, and public health. Potential applicants are encouraged to

contact MCI for questions regarding eligibility. Applicants with projects that may not conform specifically to programmatic guidelines are encouraged to contact MCI to discuss a potential application.

Applicants focusing on the development of male contraceptives are encouraged to submit projects aligned with MCI Priority Research Areas, which include the following:

- Approaches that target the post-meiotic phase of spermatogenesis
- Approaches that target sperm functions required for normal fertilization, such as sperm motility and the acrosome reaction
- Approaches that target post-testicular processes required for fertility, including epididymal maturation and sperm transport in the excurrent ducts
- Other approaches that could lead to on-demand or otherwise fast-acting, reversible male contraceptives
- Approaches with the potential to result in Multipurpose Prevention Technology (MPT) products that prevent pregnancy and act against sexually transmitted infections such as HIV.
- Approaches that repurpose existing chemical entities for contraception that may be currently approved by the US Food and Drug Administration or other regulatory authorities for other indications.

Applications not within MCI Priority Research Areas but fulfilling other eligibility criteria will be reviewed alongside applications aligned with MCI Priority Research Areas using the same criteria and evaluative process.

Applications in the following areas are considered outside of MCI interests and will not be reviewed:

- Development of male contraceptives involving the exogenous administration of steroid hormones
- Approaches that induce active immunity
- Male or female condom development
- Product development of contraceptives that are delivered to female users
- Approaches that permanently inhibit fertility, e.g. cause sterility or other defects in reproduction after cessation of treatment

# Section IV: Application procedure

Application Documents A-E must be submitted by April 15, 2022 to [fellowships@malecontraceptive.org](mailto:fellowships@malecontraceptive.org) as a single PDF, formatted in Arial 11 point font on 8.5 x 11 inch pages with one inch margins.

Application Documents F: Letters of Support must be submitted by April 15, 2022, directly to [fellowships@malecontraceptive.org](mailto:fellowships@malecontraceptive.org) by the letter writer with the subject line "CANDIDATE NAME - Letter of Support."

## Application documents

### A. Project Narrative - (6 pages maximum, including figures and references)

The plan for the project should concisely describe the present state of knowledge as it relates to the proposed project, as well as the importance, scope, specific aims, and objectives of the proposed work to be performed. Include figures when necessary. Please include the applicant and sponsoring principal investigator(s) name, title, institution, and contact information.

Successful applications will include a specific hypothesis and subsequent objectives, as well as sufficient details on the approach, methods, and techniques the applicant will use to achieve objectives.

Expected outcomes should be listed in detail, and measured by specific quarterly benchmarks. Benchmarks should be specific and clear in how progress will be demonstrated. Timelines are to be presented in a written format that details specific activities performed during each quarterly period, as well as displayed visually in a format similar to Figure 1.

	2022		2023				2024		
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
<b>Specific Aim 1</b>									
Milestone 1.1									
Milestone 1.2									
<b>Specific Aim 2</b>									
Milestone 2.1									
Sub-objective 2.1									
Milestone 2.3									
<b>Specific Aim 3</b>									
Milestone 3.1									
Milestone 3.2									
Milestone 3.3									

*Figure 1 - Example Gantt Chart. Chart may be adapted in any way to fit the submitting project. Milestones may be further divided into sub-objectives and other categories as needed such that they provide detailed activities that can be related directly to the milestones to be achieved.*

**B. Personal Statement - (1 page maximum)**

The Personal Statement should concisely outline the applicants motivation, career plans, and specific interest in male contraception.

**C. Applicant CV - (4 pages maximum)**

**D. Suggested Reviewers - (1/2 page maximum)**

Please list five Principal Investigators who are experts in a field of study relevant to the proposed work, who are not current or recent (past 3 years) collaborators of the applicant or sponsoring PI, and who do not have direct personal or professional interest

in the applicant's training or career. Include email addresses. Representatives of any institutional unit that stands to receive financial benefit from a fellowship are not considered independent reviewers. Reviewers from outside the applicant's institution are preferred.

#### E. Institutional Representation (Optional)

This section provides information concerning the institution's eligibility to receive grants under U.S. tax laws and approvals of the project by reviewing bodies. Please consult with your institutional Sponsored Projects Office or equivalent for further information as to what may be included in this section.

#### F. Letters of Support

MCI requires two letters of support: One sponsor/mentor letter and one letter of reference from an expert in the field of study.

- i. Sponsor/mentor letter of support: This letter must outline, in lay terms, the relevance of the project to the MCI Fellowship Program; the training and experiences during the project that will assist the fellow to apply successfully for continued funding and to progress towards independence; and the ability of the fellow to carry out the proposed project. NOTE: If there will be more than one sponsor/mentor, the sponsors may collaborate to produce a single letter, signed by both sponsors, which includes details of how coordination of supervision will be carried out.
- ii. Letter of reference: The applicant must solicit one letter of reference from someone other than the project sponsor/mentor who is an expert in the field of study and who is not a current or recent (past 3 years) collaborator of the applicant or sponsoring PI. Examples include published authors in the field of study or experts whose work is cited as foundational in the submitted proposal. Letter writers should be provided with a copy of the final version of the application sufficiently in advance of the application deadline. Applicants are encouraged to speak with their advisor(s) to identify potential letter writers. Representatives of any institutional unit that stands to receive financial benefit from a fellowship are not considered appropriate references. Representatives from outside the applicant's institution are preferred.

These are to be submitted directly by the letter writer to [fellowships@malecontraceptive.org](mailto:fellowships@malecontraceptive.org) with the subject line "CANDIDATE NAME - Letter of Support" by the application deadline.

## Section V: Screening and notification

Fellowships will be awarded on the basis of the applicant's previous experience, academic record, and the caliber of the proposed research. Additional evaluative criteria include the quality of the mentor, the training program, and environment, as well as the relevance of the proposal to the future development and/or introduction of a male contraceptive. Proposals will be evaluated by the MCI Research Committee and at least one external reviewer.

The applicant's professional ability and promise for a research career in male contraceptive research will be highly prioritized in the evaluation of proposals, and will be assessed on the basis of the letters of recommendation, career plans, prior clinical and research training, academic transcripts, and the mentor's endorsement.

Final decisions are made by the MCI Board of Directors.

Applicants will be notified of award acceptance on or after May 31st, with an expected award start date of August 1, 2022, pending institutional approval.

## Section VI: Notices

The fellowship grant is restricted to the period indicated in the Grant Letter provided during the award process. Extension/reduction of the granted period may be considered with written request. The invitation is limited to the successful applicant specified in the Grant Letter.

The application is not to be considered confidential. Applicants wishing to disclose confidential information may contact the appropriate MCI administrator for details.

Fellows may also be asked to perform short unstructured updates via phone, digital video service, or email. Sufficient notice will be provided by MCI for these updates.

Fellows may be asked to participate in promotional efforts by MCI, which may include interviews, outreach, and other publicity. These efforts will be voluntary, and will not impact the terms of the fellowship.

MCI is required to publish a list of grantees on their website. Fellows and a short biography may be included in this information.

MCI values representation and diversity in the scientific community. Applications from women, people of color, the LGBTQIA community, and other historically marginalized groups are highly encouraged.

# Section VII: Conditions of Fellowship

Institutional Sponsored Projects Offices or other representatives must agree to the stipulations in the Terms of Agreement. The Terms of Agreement are available upon request and will be distributed simultaneously with award notification.

Fellows are responsible for submitting a yearly Progress Report 30 days before the one-year mark of the project start date. Progress Reports are to be sent to [fellowships@malecontraceptive.org](mailto:fellowships@malecontraceptive.org). It is to be in PDF format, using 11 point Arial font and with at least 0.5 inch margins. The Progress Report will be a confidential document. It is to include:

Accomplishments (four pages maximum):

- What were the major goals and objectives of the project for the current year and what was accomplished toward these goals?
- What were the benchmarks for the current year, were they met, and what is the evidence of successful research progress?
- Were there problems or delays or changes to original goals and objectives that require modification of research plans?

Progress Reports will be evaluated by the MCI Research Committee and used to determine continuation of funding. Awardees may be contacted for clarifications if questions arise during review. Continuation of funding beyond one year is contingent upon satisfactory progress and availability of funds.

A final Progress Report will be due no later than 30 days after the end of the award to [fellowships@malecontraceptive.org](mailto:fellowships@malecontraceptive.org). It is to be in PDF format, using 11 point Arial or Times Roman font and with at least 0.5 inch margins. The final Progress Report will be a confidential document. It is to include:

Accomplishments (six pages maximum):

- What were the major goals and objectives of the project for the final year and what was accomplished toward these goals?
- What were the benchmarks for the current year, were they met, and what is the evidence of successful research progress?
- What were the overall goals of the project and what was accomplished?



- What are future directions for the research, and are there plans or avenues to carry it out?
- What did this fellowship mean for your career advancement, and what are your current long-term plans?

## Section IIX: Contact

Questions about eligibility, the application, and application process are encouraged. Please contact:

Logan Nickels  
Research Director

[logan@malecontraceptive.org](mailto:logan@malecontraceptive.org)  
405-714-2083